A Phase i randomized, placebo-controlled, dose-exploration study of single-dose inhaled montelukast in patients with chronic asthma

Journal of Asthma

Volumn 47, Issue 10, 2010, Pages 1078-1084

  Philip, George ^a   Pedinoff, Andrew ^b   Vandormael, Kristel ^a   Tymofyeyev, Yevgen ^a   Smugar, Steven S ^a   Reiss, Theodore F ^a   Korenblat, Phillip E ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Princeton Center for Clinical Research   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

asthma; clinical trial; FEV1; montelukast; Phase I; placebo

Indexed keywords

MONTELUKAST; PLACEBO; SALBUTAMOL;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; DRY POWDER; ECZEMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SINUS CONGESTION;

ACETATES; ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ASTHMA; CHRONIC DISEASE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FORCED EXPIRATORY VOLUME; HUMANS; LEAST-SQUARES ANALYSIS; LEUKOTRIENE ANTAGONISTS; MIDDLE AGED; QUINOLINES; YOUNG ADULT;

EID: 78649256828     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2010.520100     Document Type: Article

References (11)

1. Storms W. Update on montelukast and its role in the treatment of asthma, allergic rhinitis and exercise-induced bronchoconstriction. Expert Opin Pharmacother 2007; 8:2173-2187.
2. De Benedictis FM, Vaccher S, de Benedictis D. Montelukast sodium for exercise-induced asthma. Drugs Today (Barc) 2008; 44:845-855.
3. Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: An evidence-based review. Drugs 2007; 67:887-901.
4. Joos S, Miksch A, Szecsenyi J, Wieseler B, Grouven U, Kaiser T, et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: A systematic review. Thorax 2008; 63:453-462.
5. Reiss TF, Sorkness CA, Stricker W, Botto A, Busse WW, Kundu S, et al. Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997; 52:45-48.
6. Reiss TF, Altman LC, Chervinsky P, Bewtra A, Stricker WE, Noonan GP, et al. Effects of montelukast (MK-0476), a new potent cys-teinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996; 98:528-534.
7. Altman LC, Munk Z, Seltzer J, Noonan N, Shingo S, Zhang J, et al. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J Allergy Clin Immunol 1998; 102:50-56.
8. Dockhorn RJ, Baumgartner RA, Leff JA, Noonan M, Vandormael K, Stricker W, et al. Comparison of the effects of intravenous and oral montelukast on airway function: A double blind, placebo controlled, three period, crossover study in asthmatic patients. Thorax 2000; 55: 260-265
9. Standardization of Spirometry. 1994 Update. American thoracic society. Am J Respir Crit Care Med 1995; 152:1107-1136.
10. PROAIR® HFA (albuterol sulfate) inhalation aerosol package insert. Teva Specialty Pharmaceuticals LLC, Horsham, PA, 2008.
11. Noonan MJ, Chervinsky P, Brandon M, Zhang J, Kundu S, McBurney J, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur Respir J 1998; 11:1232-1239.